Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Related Articles by Review for PubMed (Select 23385859)

1.

The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.

D'Arcangelo M, Wynes MW, Hirsch FR.

Curr Opin Oncol. 2013 Mar;25(2):121-9. doi: 10.1097/CCO.0b013e32835d8175. Review.

PMID:
23385859
2.

ALK inhibitors in the treatment of advanced NSCLC.

Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.

Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7. Review.

PMID:
23931927
4.

Inhibitors of the anaplastic lymphoma kinase.

Mologni L.

Expert Opin Investig Drugs. 2012 Jul;21(7):985-94. doi: 10.1517/13543784.2012.690031. Epub 2012 May 22. Review.

PMID:
22612599
5.

Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).

Di Maio M, De Marinis F, Hirsch FR, Gridelli C.

Int J Oncol. 2014 Aug;45(2):509-15. doi: 10.3892/ijo.2014.2453. Epub 2014 May 21. Review.

PMID:
24859689
6.

ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C.

Target Oncol. 2013 Mar;8(1):55-67. doi: 10.1007/s11523-012-0250-9. Epub 2013 Jan 17. Review.

PMID:
23325296
7.

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Rodig SJ, Shapiro GI.

Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90. Review.

PMID:
21154129
8.

Treatment and detection of ALK-rearranged NSCLC.

Peters S, Taron M, Bubendorf L, Blackhall F, Stahel R.

Lung Cancer. 2013 Aug;81(2):145-54. doi: 10.1016/j.lungcan.2013.03.017. Epub 2013 Jun 12. Review.

PMID:
23769207
9.

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

Tiseo M, Gelsomino F, Bartolotti M, Bordi P, Bersanelli M, Rossi G, Ardizzoni A.

Expert Rev Anticancer Ther. 2011 Nov;11(11):1677-87. doi: 10.1586/era.11.157. Review.

PMID:
22050016
10.

PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.

Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E.

Expert Opin Pharmacother. 2013 Apr;14(5):597-608. doi: 10.1517/14656566.2013.778828. Epub 2013 Mar 9. Review.

PMID:
23472711
11.

Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.

O'Bryant CL, Wenger SD, Kim M, Thompson LA.

Ann Pharmacother. 2013 Feb;47(2):189-97. doi: 10.1345/aph.1R002. Epub 2013 Feb 5. Review.

PMID:
23386065
12.

ALK inhibitors and advanced non-small cell lung cancer (review).

Rossi A, Maione P, Sacco PC, Sgambato A, Casaluce F, Ferrara ML, Palazzolo G, Ciardiello F, Gridelli C.

Int J Oncol. 2014 Aug;45(2):499-508. doi: 10.3892/ijo.2014.2475. Epub 2014 May 29. Review.

PMID:
24889366
13.

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ.

Oncologist. 2012;17(11):1351-75. doi: 10.1634/theoncologist.2012-0311. Epub 2012 Sep 18. Review.

14.

New strategies for treatment of ALK-rearranged non-small cell lung cancers.

Sasaki T, Jänne PA.

Clin Cancer Res. 2011 Dec 1;17(23):7213-8. doi: 10.1158/1078-0432.CCR-11-1404. Epub 2011 Oct 18. Review.

15.

Crizotinib for the treatment of patients with advanced non-small cell lung cancer.

Bowles DW, Weickhardt AJ, Doebele RC, Camidge DR, Jimeno A.

Drugs Today (Barc). 2012 Apr;48(4):271-82. doi: 10.1358/dot.2012.48.4.1769835. Review.

PMID:
22536569
16.

Crizotinib in the treatment of non--small-cell lung cancer.

Rothschild SI, Gautschi O.

Clin Lung Cancer. 2013 Sep;14(5):473-80. doi: 10.1016/j.cllc.2013.04.006. Epub 2013 Jun 20. Review.

PMID:
23790969
17.

Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.

de Castro-Carpeño J, Perona R, Belda-Iniesta C.

Clin Transl Oncol. 2011 Nov;13(11):774-9. doi: 10.1007/s12094-011-0732-8. Review.

PMID:
22082640
18.

Crizotinib in the treatment of non-small-cell lung cancer.

Forde PM, Rudin CM.

Expert Opin Pharmacother. 2012 Jun;13(8):1195-201. doi: 10.1517/14656566.2012.688029. Review.

PMID:
22594847
19.

Targeting anaplastic lymphoma kinase in lung cancer.

Shaw AT, Solomon B.

Clin Cancer Res. 2011 Apr 15;17(8):2081-6. doi: 10.1158/1078-0432.CCR-10-1591. Epub 2011 Feb 2. Review.

20.

Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.

Vijayvergia N, Mehra R.

Cancer Chemother Pharmacol. 2014 Sep;74(3):437-46. doi: 10.1007/s00280-014-2517-6. Epub 2014 Aug 19. Review.

PMID:
25135623
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk